Soleno Therapeutics (NASDAQ:SLNO) Sees Unusually-High Trading Volume – Still a Buy?

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) saw strong trading volume on Tuesday . 4,501,987 shares changed hands during mid-day trading, an increase of 78% from the previous session’s volume of 2,535,892 shares.The stock last traded at $52.2650 and had previously closed at $52.25.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Major catalyst — Neurocrine acquisition reported: SLNO’s recent rally was led by reports that Neurocrine agreed to acquire Soleno for about $2.9 billion (~$53/share), which explains much of the buying interest and higher intraday trading. Zacks: Soleno Therapeutics Stock Rallies
• Neutral Sentiment: Regulatory/strategic update — Soleno voluntarily withdrew its EU marketing application for its rare‑disease drug as the acquirer focuses on the U.S. market; this is a tactical move ahead of the takeover rather than new clinical data. Reuters: Soleno withdraws EU application
• Negative Sentiment: Widespread analyst downgrades — Multiple brokers (HC Wainwright, Piper Sandler, Robert W. Baird, Wolfe Research, TD Cowen, Cantor Fitzgerald, Wolfe and others) have cut SLNO to Hold from Buy/Outperform, lowering price targets toward the ~$53 level tied to the deal, reducing upside for standalone holders. MSN: HC Wainwright downgrades Soleno
• Negative Sentiment: Legal risk — Several plaintiff firms and firms issuing investor alerts (Hagens Berman, RGRD/Robbins Geller, Bernstein Liebhard, Glancy Prongay, Rosen, Faruqi & Faruqi, others) have publicized a securities‑class action tied to prior DCCR/VYKAT™ XR disclosures and set a May 5, 2026 lead‑plaintiff deadline — an overhang that can pressure the stock and create uncertainty for acquirers/targets. PR Newswire: Investor deadline in securities fraud class action

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. HC Wainwright lowered Soleno Therapeutics from a “buy” rating to a “hold” rating and lowered their price objective for the company from $100.00 to $53.00 in a report on Wednesday. Wells Fargo & Company lowered their target price on Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating for the company in a report on Friday, February 27th. Lifesci Capital lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Piper Sandler lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, Zacks Research lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. Four investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Soleno Therapeutics presently has an average rating of “Hold” and a consensus price target of $89.20.

Soleno Therapeutics Price Performance

The company has a market capitalization of $2.72 billion, a P/E ratio of 228.71 and a beta of -2.81. The company has a fifty day moving average price of $38.39 and a 200 day moving average price of $47.83. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.80 and a quick ratio of 5.55.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. On average, sell-side analysts forecast that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its holdings in Soleno Therapeutics by 18.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock worth $332,302,000 after buying an additional 1,122,015 shares in the last quarter. Wellington Management Group LLP grew its holdings in Soleno Therapeutics by 43.7% in the 4th quarter. Wellington Management Group LLP now owns 3,322,799 shares of the company’s stock worth $153,846,000 after buying an additional 1,010,704 shares in the last quarter. Vanguard Group Inc. grew its holdings in Soleno Therapeutics by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock worth $141,695,000 after buying an additional 253,212 shares in the last quarter. Avoro Capital Advisors LLC grew its holdings in Soleno Therapeutics by 12.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock worth $134,270,000 after buying an additional 322,223 shares in the last quarter. Finally, State Street Corp grew its holdings in Soleno Therapeutics by 21.9% in the 4th quarter. State Street Corp now owns 2,649,626 shares of the company’s stock worth $122,678,000 after buying an additional 476,590 shares in the last quarter. 97.42% of the stock is owned by institutional investors.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.